tru Independence’s Inovio Pharmaceuticals INO Stock Holding History

tru Independence’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-198	Closed	-$63	–	587
2020 Q2	$63	Buy	+198	New	+$31.8K	0.01%	352

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

tru Independence's INO Position: Q3 2020 in Review

tru Independence sold out of Inovio Pharmaceuticals (INO) in Q3 2020, closing a stake of 198 shares — an estimated $63 sold.

tru Independence first reported a position in INO in Q2 2020 and held it in 1 quarter. The position peaked at $63 in Q2 2020. 212 funds tracked by Wall St. Rank hold INO as of Q3 2020.

tru Independence reported no remaining Inovio Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
tru Independence sold 198 Inovio Pharmaceuticals shares in Q3 2020, an estimated $63.
tru Independence first reported a position in Inovio Pharmaceuticals in Q2 2020 and held it in 1 quarter.
tru Independence's Inovio Pharmaceuticals position peaked at $63 in Q2 2020.
212 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.